Aims To evaluate the evidence for the novel dual sodium-glucose co-transporter-1 (SGLT1) and -2 (SGLT2) inhibitor, sotagliflozin, which may enhance the efficacy of SGLT2 inhibitors by additionally reducing intestinal glucose absorption.
Conclusions
The current evidence for sotagliflozin in diabetes appears promising. Further studies sufficiently powered to assess present and emerging safety concerns, as well as to identify individuals for whom sotagliflozin may be of particular benefit/harm would now be informative for regulatory decision-making. Direct comparisons with existing SGLT2 inhibitors are also needed to determine relative safety/efficacy profiles for the different indications.
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Background Sodium-glucose co-transporters (SGLTs) are widely expressed throughout the body [1] . With the exception of SGLT3, they facilitate the secondary active co-transport of sugars and sodium ions across the apical membrane; sodium extrusion by an ATP-dependent sodium-potassium pump in the basolateral membrane maintains an electrochemical potential, allowing glucose to enter the cell against its concentration gradient [2] . Glucose passage across the basolateral membrane and into the blood is then mediated by facilitative glucose transporter-2.
Six members of the SGLT family have been characterized to date, each with a different expression pattern and substrate affinity [1] . Of particular interest in diabetes are SGLT1 and SGLT2. The former is predominantly expressed on the brush border membrane of the small intestine, with the latter prevalent along the proximal convoluted tubules of the nephron [3] . While SGLT1 has a low capacity but high affinity for glucose, the inverse is true for SGLT2 [4] . Interestingly, both of these transporters appear to be upregulated in individuals with diabetes, who present with elevated levels of intestinal glucose absorption and reduced glycosuria [5] [6] [7] . This is a maladaptive response, contributing to the maintenance of pathological hyperglycaemia. Disruption of glucose transport by one or both of these proteins is therefore an attractive approach to combatting hyperglycaemia.
Approximately 90% of glucose in the glomerular filtrate is reabsorbed via SGLT2 [8] ; thus, its blockade offers the potential for reducing circulating plasma glucose. Furthermore, as glucose filtration is dependent on its concentration
Correspondence to: Joan Minguet. E-mail: joan@irmedica.com ª 2018 Diabetes UK in the blood, hypoglycaemia is unlikely [9] . However, the capacity of SGLT2 inhibitors, to reduce glucose re-uptake is lower than expected given the high degree of transporter inhibition observed [10, 11] . One hypothesis for this phenomenon is a compensatory response from SGLT1, resulting in increased intestinal and late proximal tubule glucose absorption [12] . Accordingly, dual inhibition of SGLT1 and SGLT2 may amplify urinary glucose excretion. Furthermore, intestinal SGLT1 inhibition would reduce postprandial glucose (PPG) excursions and result in the delivery of more glucose to the lower bowel, stimulating gut hormones that suppress glucagon release and appetite [13] . The latter may assist with weight loss, a common goal in individuals with Type 2 diabetes. Hypertension may also be improved by SGLT1/SGLT2 blockade, the combined result of reduced body weight, osmotic diuresis and a negative sodium balance, which promotes smooth muscle relaxation [14] ; however, concerns over gastrointestinal disturbances have been expressed.
Several phase III clinical trials of the dual SGLT1/SGLT2 inhibitor, sotagliflozin (LX4211), in Type 1 diabetes mellitus have recently been completed [15] [16] [17] , warranting an updated review of the literature. In the present review, evidence for the pharmacokinetics/dynamics, efficacy and safety of sotagliflozin are examined and contextualized within the literature on existing SGLT2 inhibitors.
Methods
A PubMed literature search including the terms 'sotagliflozin', 'LX4211', 'SGLT' and 'diabetes' was carried out. The returned literature was screened for pertinent information on the pharmacokinetics, pharmacodynamics, safety and efficacy of sotagliflozin in Type 1 and 2 diabetes, alongside data on similar existing inhibitors. No publication year limits were applied to ensure inclusion of all applicable information, although older papers were critically evaluated for their contemporary relevance. Reference lists were reviewed to identify additional sources of information. Peer-reviewed publications involving human participants were the preferred sources, followed by government, statutory and national professional organization publications. US Food and Drug Administration (FDA) and European Medicines Agency websites were also consulted to identify any applicable regulatory information, while ClinicalTrials.gov searches were carried out to avoid overlooking any ongoing or unpublished research. This led to a further search for conference abstracts reporting 'inTandem' study data.
Existing SGLT inhibitors for diabetes mellitus
No dual SGLT1/SGLT2 inhibitors are currently available for use in clinical practice; however, several SGLT2-specific inhibitors have been approved for the treatment of Type 2 diabetes in Europe and the USA: canagliflozin (Invokana â ;
Janssen Pharmaceuticals, Inc.), dapagliflozin (Farxiga â ;
AstraZeneca Pharmaceuticals LP) and empagliflozin (Jardiance â ; Boehringer Ingelheim Pharmaceuticals, Inc.). Although a small amount of transient SGLT1 inhibition has been detected for canagliflozin [18] , it is not considered a dual inhibitor due to its low potency (>250 times lower for SGLT1 than SGLT2) [19] .
The clinical development of these agents has been largely focused on Type 2 diabetes, used either as a monotherapy or as part of a multi-drug combination. This is likely attributable to the popularity and growth of oral antidiabetic drugs for this indication, contrasted against Type 1 diabetes, for which optimization of insulin alone is a well established and highly efficient first-line strategy. Pivotal phase III trials in Type 2 diabetes have shown each SGLT2 inhibitor to result in sustained improvement in glycaemic control, without increasing hypoglycaemia risk and with substantial weight loss advantages [20] [21] [22] . All three SGLT2-specific inhibitors have also been evaluated as an adjuvant to insulin in individuals with Type 1 diabetes, with reductions in HbA 1c , body weight, lipid levels and insulin dose reported [23] [24] [25] . In spite of this, none are currently approved for the treatment of Type 1 diabetes, which appears to be the priority indication for sotagliflozin development.
No direct comparisons among the different SGLT2 inhibitors have been carried out to date, and most existing meta-analyses assess gliflozins as a class rather than individually [26] [27] [28] . However, one recent meta-analysis of data from 23 997 individuals with Type 2 diabetes from 38 randomized controlled trials, found that reductions in HbA 1c , fasting plasma glucose (FPG) and systolic blood pressure (SBP) relative to placebo were greater for canagliflozin 300 mg than for empagliflozin or dapagliflozin [29] .
What's new?
• Several sodium-glucose co-transporter-2 (SGLT2) inhibitors are available for the treatment of Type 2 diabetes mellitus; however, sotagliflozin is the first dual sodiumglucose co-transporter-1/SGLT2 inhibitor to reach phase III trials for the Type 1 diabetes indication.
• Sotagliflozin has demonstrated good efficacy in improving glycaemic control in Types 1 and 2 diabetes, with additional weight loss benefits; however, several drugrelated adverse events remain a concern, including diabetic ketoacidosis, diarrhoea and genital mycotic infection.
• The data presented in this review suggest that regulatory approval for sotagliflozin in Type 1 diabetes may be on the horizon, potentially providing physicians with a novel option for combatting the metabolic disorder.
This suggests that canagliflozin may be the agent to beat in terms of efficacy, potentially because of its additional SGLT1 inhibitory effect [30] . However, heterogeneous study designs and variable participant characteristics mean that results should be interpreted with caution. In terms of safety, all SGLT2 inhibitors have been associated with an elevated risk of genitourinary infections as a result of increased glycosuria [28, 31] . More seriously, the risk of diabetic ketoacidosis (DKA) has also been seen to increase [25, [32] [33] [34] , with an FDA warning applicable to all drugs of this class [35] [36] [37] . Warnings about acute kidney injury have also been issued for canagliflozin and dapagliflozin [38] , with a boxed warning regarding increased risk of leg/foot amputation in place for canagliflozin [35] . Any agent retaining a high level of efficacy whilst minimizing such adverse events would be of particular utility in the clinic. In future, well-designed, head-to-head comparisons between SGLT inhibitors in diabetes will be required to establish their relative safety/efficacy profiles. Until such data become available, any apparent differences are purely speculative.
Introduction to sotagliflozin
Sotagliflozin is an orally available dual SGLT1/SGLT2 inhibitor (see Table 1 for drug overview). Its pharmacological profile compared with the available SGLT2 inhibitors can be found in Table 2 , while its key clinical trials are summarized in Tables 3 and 4 . For thorough details of its development, readers are directed to an excellent summary by Lapuerta et al. [34] .
Chemistry
Sotagliflozin [(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol] has the molecular formula C 21 H 25 ClO 5 S and a molecular mass of 424.94 g/mol [39, 40] . It is a crystalline solid that is sparingly soluble in organic solvents (30 mg/ml) and very slightly soluble in aqueous buffers (<1 mg/ml) [40] .
Pharmacodynamics
In vitro studies in HEK293 cells have demonstrated sotagliflozin to have a half-maximum inhibitory concentration (IC 50 ) of 0.0018 lΜ for SGLT2 and of 0.036 lM for SGLT1 [39, 41] . Although its affinity is greater for SGLT2, the difference is only 20-fold, in comparison with >250-fold for canagliflozin [19] . Nevertheless, it is important to note the potential effect of glucose concentration and plasma protein binding on selectivity, with the latter reported to be as high as 97.7% for sotagliflozin in murine models [42] . Sotagliflozin's glucose-lowering capacity is mediated by a number of mechanisms, with dosing directly before breakfast shown to maximize its inhibitory effects [43] .
In individuals with Type 2 diabetes, a single 300-mg dose of sotagliflozin led to a 56-g increase in 24-h urinary glucose excretion relative to baseline [41] , consistent with SGLT2 inhibition. This is greater than the highest recorded 24-h urinary glucose excretion of 44 g/day after a 300-mg dose in healthy individuals [39] , likely attributable to the upregulation of transporters in people with diabetes. Nonetheless, compared with SGLT2 inhibitors, the effect appears modest [44] , probably as a result of the inhibition of intestinal glucose absorption by SGLT1 leading to a lower concentration of circulating glucose for filtration by the kidneys.
The mean area under the curve (AUC) values for glucagonlike peptide (GLP)-1 and peptide YY over the 13 h following a single sotagliflozin 300-mg dose showed mean increases from baseline (14.4 and 96 pmol/h/l, respectively), with notable peaks after meals [41] . This highlights an additional mechanism of action, whereby SGLT1 blockade results in the increased delivery of consumed glucose and its bacterial fermentation products to the lower bowel, stimulating intestinal L-cells to release these hormones [45] . GLP-1 inhibits glucagon secretion from pancreatic a-cells in individuals with Type 2 diabetes [46] , which reduces stimulation of hepatic glucose production, while peptide YY has an anoretic effect [47] , contributing to a potential reduction in glucose ingestion.
The mean AUC value for plasma glucose in individuals with Type 2 diabetes was reduced by 13% over the 13 h following a single sotagliflozin 300-mg dose [41] . This is similar to the 13% reduction seen 24 h after an initial canagliflozin 100-mg dose [44] ; however, in a multipledosing study, AUC 0-4 values for plasma glucose by day 27 were~40% lower for participants on sotagliflozin 150 mg or 300 mg once daily compared with placebo, with a gradual decrease having taken place since day 1 [41] . This suggests the glucose-lowering effect of sotagliflozin may increase over time. Conversely, very little change in plasma glucose levels was seen with canagliflozin from day 7 onwards [44] .
The dose-dependent effect of sotagliflozin has been indicated by several clinical trials [41, 48, 49] . One exception is urinary glucose excretion, which has been shown to plateau from the 200-mg once-daily dose onwards [48] . This suggests 
Pharmacokinetics and metabolism
Although early studies found oral sotagliflozin solutions to have a higher degree of bioavailability compared with the solid tablets [41] , all subsequent clinical trials have used the latter drug formulation. The pharmacokinetics discussed in the present review therefore pertain to oral tablet administration, unless otherwise stated.
Absorption and accumulation
After a single dose of sotagliflozin 300 mg, mean values for peak serum concentration (C max ) were found to be 105 ng/ml for 2 9 150 mg tablets and 135 ng/mL for 6 9 50 mg tablets, with a rapid onset of absorption and a median (range) time to maximum plasma concentration (T max ) of 3 (0.5-3) h [41] ; however, on day 14 of multiple once-daily dosing with a 300-mg liquid solution, a mean C max value~27% higher than that on day 1 was seen, which was almost identical to the value recorded at 28 days. This indicates a small amount of accumulation, and suggests that a steady-state is reached by 14 days.
Metabolism, distribution and elimination
The T 1/2 for sotagliflozin on once-daily dosing day 28 has been reported to be between 13.5 and 20.7 h in individuals with Type 2 diabetes and normal renal function [41] , suggesting the appropriateness of once-daily dosing. Plasma levels undergo a biphasic decline, with an initial phase of rapid distribution followed by a slow terminal elimination phase [51] . The majority is excreted as a glucuronide metabolite in urine, with the remainder eliminated as an unchanged drug in faeces [51] . Apparent total clearance from plasma was reported to be 350-395 l/h after a single dose, with steady-state clearance rate ranging between 202 and 241 l/h [41] .
In individuals with Type 2 diabetes and moderate or severe renal impairment, the T 1/2 values on day 7 of once-daily dosing were found to be 18.1 and 16.6 h, respectively [52] . These are similar to the values reported for those who had kidney function parameters within the normal range [41] and suggest that, despite its predominantly renal clearance route, the plasma elimination of sotagliflozin is not substantially altered in those with kidney disease. This idea is supported by an apparently moderate degree of accumulation, which was not greater in those with severe compared with moderate impairment [52] . In contrast, studies of canagliflozin and empagliflozin in people with renal impairment have shown T 1/2 values to rise alongside increasing renal impairment, accompanied by increasing drug exposure [53, 54] ; however, it should be noted that no direct comparison to individuals without renal impairment was included in the sotagliflozin study and that the number of participants was low [52] .
Efficacy

Type 2 diabetes
In 2012, the results of a 28-day, phase II sotagliflozin trial in 36 individuals with Type 2 diabetes after metformin washout were published [41] . Participants were randomized to receive liquid sotagliflozin 300-mg or 150-mg formulations once daily, or placebo. The effect of sotagliflozin on 2-h PPG increased over time, such that values on day 28 were 2.8 and 3.2 mmol/l below baseline for the lower and higher dose, respectively. FPG values on day 29 were an average of 2.8 mmol/l (29.7%) and 3.7 mmol/l (36.2%) lower than at baseline, with mean HbA 1c values reduced to 54 mmol/mol (7.1%) and 56 mmol/mol (7.3%), respectively. In both cases, these reductions were significantly greater compared with placebo, providing evidence for the efficacy of sotagliflozin as a monotherapy in Type 2 diabetes. Further potential benefits highlighted by the study were a lower degree of insulin resistance accompanied by a higher glucose tolerance in sotagliflozin-treated participants, with trends towards greater blood pressure and weight reductions. The results of a 12-week, phase II dose-finding study in 299 participants were published in 2015 [48] . Individuals with Type 2 diabetes who were inadequately controlled on metformin monotherapy were randomly assigned to add placebo or sotagliflozin 75 mg once daily, 200 mg once daily, 200 mg twice daily, or 400 mg once daily to their existing treatment regime. A clear dose-dependent glycaemic effect was noted, with mean decreases in HbA 1c from baseline of 4 mmol/mol (0.4%), 5 mmol/mol (0.5%), 8 mmol/mol (0.8%) and 9 mmol/mol (0.9%) across increasing dose groups at 12 weeks, compared with just 1 mmol/mol (0.1%) for the placebo [48] . The same trend was seen for FPG (-0.5, -1.0, -1.5 and -1.5 vs +0.1 mmol/l). Weight loss was highest in patients taking the 200 mg dose twice daily, with smaller, comparable losses seen in those taking the 200 mg and 400 mg once-daily doses. Reductions in SBP, however, were greatest in the 200-mg once-daily group (-2.8 mmHg) followed by the 200-mg twice-daily and 400-mg groups (-2.2 and -1.6 mmHg vs -0.5 mmHg for placebo). These results indicate that sotagliflozin may be a valuable adjunct to metformin in individuals with Type 2 diabetes, with the 400-mg once-daily dose offering the greatest glycaemic control, but remaining limited in terms of additional benefits. Accordingly, both 400-mg and 200-mg once-daily doses have been carried forward to two phase III trials in Type 2 diabetes [27, 28] . Currently in the recruitment stage, the first will assess the utility of sotagliflozin as an adjunct to metformin in~500 participants over 26 weeks, with completion expected in March 2019 [28] . The second is of a similar design, but aims to enrol~400 participants with Type 2 diabetes that are naive to antidiabetic therapy and poorly controlled by lifestyle modifications, with completion expected in March 2018 [27] . In both studies, key outcome measures include the change in HbA 1c relative to baseline, as well as changes in FPG, PPG, SBP and body weight.
A further notable trial examined the safety and efficacy of sotagliflozin in people with moderate-to-severe renal impairment (estimated GFR <60 ml/min/1.73 m 2 ) [52] ; this is a population of particular interest, given that SGLT2 inhibitor efficacy is poor in such individuals [53] [54] [55] [56] . Addition of sotagliflozin 400 mg once daily to existing basal insulin and/ or single oral antidiabetic drug treatment resulted in reduced PPG (AUC 1-4 -6.3 mmolÁh/l) and FPG (-1.5 mmol/l; P < 0.001) levels at 7 days, compared with no reduction in the placebo group. A similar improvement occurred in the subset of participants with an estimated GFR of <45 ml/min/1.73 m 2 , despite their predictably lower urinary glucose excretion.
Thus, sotagliflozin may be of benefit to individuals with reduced kidney function, especially in light of their currently limited choice of non-insulin therapies [57] . Also of interest is a trial that explored the combination of sotagliflozin with a dipeptidyl peptidase-4 (DPP-4) inhibitor [58] . After metformin washout, 18 participants were administered a single dose of sotagliflozin 400 mg, sitagliptin 100 mg or a combination of the two in a three-way crossover design. FPG levels improved to a significantly greater extent with combination therapy than with sotagliflozin or sitagliptin monotherapy over the first 13 h after dosing (12.3 vs 13.1 and 13.4 mmolÁh/l, respectively), accompanied by a greater increase in GLP-1 activity, which is in line with the upregulatory effect of sotagliflozin on GLP-1 release and the role of DPP-4 inhibitors in maintaining its active state. This synergistic effect may prove advantageous for the treatment of Type 2 diabetes, with the appetite-diminishing effect of both agents an additional advantage for overweight and obese individuals. This study paves the way for further trials involving sotagliflozin and DPP-4 inhibitor combinations.
Type 1 diabetes
The results of inTandem3, a worldwide phase III randomized controlled trial, were published in September 2017 [15] . The study population consisted of 1402 individuals with Type 1 diabetes, randomized to receive sotagliflozin 400 mg once daily or placebo in addition to their existing basal insulin treatment over 24 weeks. The primary endpoint, the proportion of participants achieving HbA 1c ≤ 53 mmol/mol (7.0%) without severe hypoglycaemia or DKA at study end (henceforth referred to as 'net benefit'), was met by a significantly higher proportion of those taking sotagliflozin compared with placebo (28.6% vs 15.2%; P < 0.001), with similar values presented for HbA 1c target achievement alone (29.6% vs 15.8%). Significantly greater reductions in HbA 1c (-8 mmol/mol [-0.8%] vs -3 mmol/mol [-0.3%]) and total daily insulin dose (placebo-corrected value: -5.3 units) were also noted in the sotagliflozin group, with those who had SBP values >130 mmHg at baseline experiencing a 3.5-mmHg greater reduction in SBP by week 16 compared with their placebo counterparts. In addition, while participants in the placebo group gained weight, those on sotagliflozin lost weight, with a least squares mean weight change from baseline of -2.98 kg. This suggests that sotagliflozin has the potential to improve glycaemic control in individuals with Type 1 diabetes, with concomitant benefits such as reductions in insulin requirements, weight and blood pressure. However, the relatively short follow-up remains a concern, and safety issues must also be considered.
The results of two similar phase III studies [inTandem1 (USA) and inTandem2 (Europe) [16] ] were presented at the American Diabetes Association 77 th Scientific Session in 2017. Both found a significantly greater reduction in HbA 1c with sotagliflozin 200 and 400 mg compared with placebo, as well as a greater net benefit (inTandem1: 33.5% and 43.5% vs 21.6%; inTandem2: 31.8% and 32.3% vs 15.2%). Given the apparent similarity between the outcomes of participants on 200-mg and 400-mg doses, it is possible that ª 2018 Diabetes UK selection of the 400 mg dose for the larger-scale inTandem3 study without first performing a Type 1 diabetes dose-finding study was hasty. Indeed, a 12-week phase II trial (inTandem4) comparing sotagliflozin 75 mg, 200 mg and 400 mg once daily with placebo was only completed approximately 1 year after phase III trials had begun [49] . This randomized study, which involved 141 individuals with Type 1 diabetes on stable insulin therapy, found the greatest reduction in HbA 1c to have occurred in those receiving the 200-mg dose (least squares mean difference vs placebo: -5 mmol/mol [-0.5%]; P < 0.001), followed by the 400-mg dose (-4 mmol/ mol [0.4%]; P = 0.006), reiterating the idea that a lower dose may be sufficient; however, the reduction in 2-h PPG values (-2.7 mmol/l; P = 0.006) and SBP (-14.3 mmHg; P = 0.013) relative to placebo only reached significance in the 400-mg group, perhaps highlighting potential additional advantages of the higher dose. Further dose-comparison studies may be merited, especially given that lower doses typically result in lower rates of adverse events.
Safety and tolerability
The majority of studies have found any adverse events to occur at a similar frequency in placebo-and sotagliflozintreated participants [15-17, 41, 48, 59, 60] ; however, the phase III trials conducted to date have all reported higher rates of serious adverse events in the sotagliflozin groups, particularly in individuals receiving the 400-mg dose (inTandem1: 6.9% vs 3.3%; inTandem2: 4.2% vs 3.5%; inTandem3: 6.9% vs 3.4%). The same is true of study drug discontinuation because of an adverse event (inTandem1: 3.8% vs 1.5%; inTandem2: 3.0% vs 1.6%; inTandem3: 6.3% vs 2.3%) [15] [16] [17] . Although these rates are low, the potentially increased risk with sotagliflozin is concerning.
Gastrointestinal events
Several studies have reported higher rates of nausea with sotagliflozin 400 mg compared with placebo (Rosenstock et al. [48] : 10.2% vs 5.0%; Sands et al. [59] : 25% vs 6%; inTandem3 [15] : 2.0% vs 1.3%), although rates do not seem to be particularly elevated with lower doses [41, 48, 49] . However, data regarding this outcome, are not yet available from the inTandem1 and inTandem2 trials, meaning that lower doses have only been assessed in small phase II studies to date. Furthermore, a lack of statistical analysis means that the significance of apparent differences in nausea rates cannot be properly evaluated. The same dose-dependent trend has been noted for diarrhoea, with inTandem2 and inTandem1 trials reporting rates of 7.2% and 9.9% in sotagliflozin 400 mg users, 5.4% and 7.2% in sotagliflozin 200 mg users, and 3.9% and 5.6% in the placebo group, respectively [16, 17] . While diarrhoea was generally less common in inTandem3, the rate was still twofold higher in the sotagliflozin 400-mg compared with the placebo group (4.1% vs 2.3%) [15] . This recurring trend suggests that gastrointestinal disturbances may be pertinent adverse events in sotagliflozin users, which may amount to reduced adherence over the longer term. Indeed, while the inTandem3 authors emphasize the transient and mild-tomoderate nature of diarrhoea, reporting discontinuation in only 0.4% of participants for this reason [15] , the relatively short timescale of the study means that findings may not reflect real-world tolerability and persistence. Identification of individuals most likely to have gastrointestinal events on sotagliflozin would be informative, especially once data for a longer timeframe become available. In addition, given its encouraging efficacy and apparent potential to limit gastrointestinal effects, the 200-mg sotagliflozin dose may merit further consideration.
Diabetic ketoacidosis
Ketoacidosis is a serious adverse event associated with the use of SGLT2 inhibitors, with rates of 6.0-9.4% and 4.3-5.1% reported for those with Type 1 diabetes on canagliflozin 300 and 100 mg, respectively, at 18 weeks [25, 34] . Phase III sotagliflozin studies also indicate a dose-dependent trend, with 24-week rates of 1.1-3.1% in participants on a 400-mg dose, 0.4-1.1% in those on a 200-mg dose, and 0-0.6% in those on placebo [15] [16] [17] . While these are lower than the values reported for canagliflozin, the inTandem3 authors note that intensive measures to mitigate the risk of DKA were employed in sotagliflozin trials, and that a higher proportion of individuals may experience this adverse event in a real-world setting [15] . Furthermore, head-to-head comparisons would be required to confirm the observed differences. Regardless, the life-threatening nature of DKA cannot be ignored. Its higher frequency in sotagliflozin users with insulin pumps compared with those without insulin pumps (4.4% vs 2.1%) [15] may present an opportunity for limiting DKA risk, either by avoiding use in this population or through closer monitoring/recognition of pump failure. Furthermore, the lower DKA rate associated with sotagliflozin 200 mg may, again, make this dose more attractive.
Genitourinary infections
The SGLT2 inhibitor class has been previously associated with genitourinary infections, attributable to increased urinary glucose excretion [61, 62] . In a phase II, Type 2 diabetes study, a higher proportion of women on sotagliflozin had experienced a genitourinary event by 12 weeks compared with those taking a placebo, with an apparent dosedependent effect (4.0%, 7.0% and 9.7% for 75-mg, 200-mg and 400-mg daily doses, respectively) [48] . Phase III trials of sotagliflozin in individuals with Type 1 diabetes seem to confirm this dose-dependency, with genital mycotic infection rates of 6.1-7.3% in those taking sotagliflozin 200 mg and 6.4-10.3% in those taking sotagliflozin 400 mg (placebo:
1.6-3.4%) [15] [16] [17] . Again, the safety advantage of the 200-mg dose is highlighted. While the authors state that genitourinary events were easily resolved with standard treatment and that there was a low rate of sotagliflozin discontinuation for this reason [15, 48] , the long-term effect of such infections has not been examined. Similarly to diarrhoea, recurrent, non-serious adverse events tend to impair quality of life and ultimately result in poorer adherence and/or treatment termination.
Hypoglycaemia
Unsurprisingly, all sotagliflozin trials in insulin-naive individuals with Type 2 diabetes have reported no incidence of hypoglycaemia [41, 48] . In terms of Type 1 diabetes, phase III trials found the rate of severe hypoglycaemia to be similar in the sotagliflozin and placebo groups (sotagliflozin 400 mg: 2.3-4.6%; sotagliflozin 200 mg: 3.8-4.2%; placebo: 2.4-6.7%) [15] [16] [17] , indicating good safety in this respect; however, in the subgroup of participants in the inTandem3 study with an insulin pump, severe hypoglycaemia appeared to be more common in sotagliflozin users (3.6% vs 1.8%) [15] . Again, this highlights pump use as a potential risk factor for adverse events while taking sotagliflozin, which requires further investigation.
Renal injury and amputations
Two recent FDA warnings stress the increased risk of foot/leg amputations and acute kidney injury with certain SGLT2 inhibitors [35, 38] . Neither adverse event has been specifically assessed in sotagliflozin users, given the novelty of the warnings and the short timescale of sotagliflozin studies. Specific risk assessments should now be carried out to determine their relevance in the use of this agent.
Regulatory affairs
The original developers of sotagliflozin, Lexicon Pharmaceuticals, began a collaboration with Sanofi in November 2015, including a licence agreement for worldwide development, management and commercialization [63] . Although sotagliflozin is not currently approved for any indication, the recent results of the inTandem studies will probably propel the drug towards regulatory consideration for Type 1 diabetes, with Sanofi preparing to file European Medicines Agency and FDA applications within the first 6 months of 2018 [63] . In addition, a paediatric investigation plan for evaluating sotagliflozin as an adjunct to insulin therapy in children with Type 1 diabetes received European Medicines Agency agreement in October 2014, with completion mandatory before March 2024. Being slightly behind in development, regulatory approval for Type 2 diabetes is unlikely to be sought for some time.
Conclusions
Sotagliflozin is the only dual SGLT1/SGLT2 inhibitor in latestage clinical development at this time. It has predictable pharmacokinetics and has demonstrated convincing efficacy for improving glycaemic control in individuals with Type 1 and Type 2 diabetes, both as a monotherapy and as an adjunct to metformin or insulin. Furthermore, its weight-loss effects may prove attractive, especially where weight gain on insulin is a concern. Several pertinent safety concerns remain, however, with a current lack of formal analysis regarding the significance and long-term importance of the observed adverse events. While DKA and genitourinary infections appear to occur at nominally lower rates in those taking sotagliflozin compared with the approved SGLT2 inhibitors, no direct comparisons exist to corroborate these observations. Furthermore, the clinical relevance of DKA is not diminished by its apparently lower incidence, being a serious and potentially fatal complication. Furthermore, given that specific measures were taken to minimize DKA in phase III sotagliflozin studies, it is likely to affect more individuals in real-world clinical practice, mandating particular caution moving forwards. As such, further exploration of inTandem3 data for insulin pump-users would be informative to explore the potential contribution of pump failure to DKA, with unambiguous identification of high-risk individuals (such as those with poor insulin adherence) paramount. Lastly, unlike the approved SGLT2 inhibitors, sotagliflozin is associated with gastrointestinal disturbances. While such non-serious adverse events may appear trivial at first glance, recurrence is probable with chronic use, which is likely to have an impact on long-term quality of life, adherence and persistence. Use of lower sotagliflozin doses may reduce the proportion of individuals adversely affected. To this end, studies assessing the safety and efficacy of both 400-mg and 200-mg doses over a longer timescale would be informative for regulatory decision-making.
Assuming that the remaining safety questions are satisfactorily addressed, sotagliflozin is likely to gain approval as an adjuvant to insulin therapy in Type 1 diabetes. It has also shown potential for use as part of an oral antidiabetic drug combination in Type 2 diabetes; however, given that metformin is already associated with weight-loss benefits, a high degree of glycaemic control and few adverse events in individuals with Type 2 diabetes, sotagliflozin may struggle to compete as a monotherapy. Nevertheless, its additional benefits, including smaller PPG excursions, lower insulin requirements, and appetite suppression, are likely to help its cause. In addition, contrary to other SGLT2 inhibitors, the efficacy of sotagliflozin appears to be well preserved in individuals with renal impairment, probably as a result of its additional SGLT1 inhibitory effect. Given that many of the available antidiabetic agents are contraindicated in this subset of people, sotagliflozin may be a much-needed ª 2018 Diabetes UK alternative. Considering that DPP-4 inhibitors can also be used in individuals with renal impairment, the apparent synergistic relationship between sotagliflozin and sitagliptin holds particular promise.
In general, longer-term, larger-scale, direct comparison studies are needed across Type 1 and Type 2 diabetes indications to corroborate current findings and better characterize the relative efficacy/safety profiles of the SGLT inhibitors. These studies will also answer the pending question as to whether dual SGLT1/2 inhibition offers any real advantage over SGLT2-specific inhibition in clinical practice. The resulting data will be essential for informing future treatment decisions.
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